Text Size

Neurocognitive Enhancement in Major Depressive Disorder (MDDNET)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christopher Bowie, Queen's University
ClinicalTrials.gov Identifier:
NCT00998569
First received: October 14, 2009
Last updated: March 20, 2012
Last verified: March 2012
History of Changes

October 14, 2009
March 20, 2012
October 2009
March 2012   (final data collection date for primary outcome measure)
Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00998569 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neurocognitive Enhancement in Major Depressive Disorder
Neurocognitive Enhancement in Major Depressive Disorder

The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Disorder
  • Behavioral: Neurocognitive Enhancement
    Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
  • Behavioral: Wait List Control
    Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
  • Experimental: Neurocognitive Enhancement
    Intervention: Behavioral: Neurocognitive Enhancement
  • No Intervention: Wait List
    Intervention: Behavioral: Wait List Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or Female.
  2. Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.

Exclusion Criteria:

  1. Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
  2. Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
  3. Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00998569
PSYC-092-09
No
Christopher Bowie, Queen's University
Queen's University
Not Provided
Principal Investigator: Christopher Bowie, PhD Queen's University
Queen's University
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP